Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
5 lutego 2019 zaktualizowane przez: Montefiore Medical Center
Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant
Patients with kidney failure have underlying bone disease at the time of transplant. Fractures of various bones can be as high as 22%. Medication required for the transplant plays a role in bone loss.
Bisphosphonates are used in the general population to treat bone loss of osteoporosis and steroid-induced bone loss. While previous studies, using various bisphosphonates, have shown preservation of bone mineral density in renal transplant recipients, we have demonstrated that pamidronate, a second generation bisphosphonate, is associated with low bone turnover while still preserving bone mineral density. Improved bone mineral density is associated with decreased fracture risk in the general population, while low bone turnover may be associated with increased fracture in dialysis patients.
The purpose of this study is to determine whether risedronate, a third generation bisphosphonate, is effective in preserving bone density when given prophylactically following renal transplantation and whether it is associated with low bone turnover at one year following renal transplantation.
Przegląd badań
Status
Zakończony
Warunki
Interwencja / Leczenie
Szczegółowy opis
Participants who receive a living donor kidney transplant undergo a bone biopsy at the time of kidney transplant and after one year of protocol.
Once adequate kidney function is established, both groups take by mouth a weekly capsule (the control group has a placebo; the treatment group has risedronate 35 mg).
Both groups undergo baseline, 6 month and 12 month dual energy x-ray absorptiometry (DEXA) bone mineral density scans.
Both groups undergo bone hormonal studies at regular intervals.
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
60
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
New York
-
Bronx, New York, Stany Zjednoczone, 10467
- Montefiore Medical Center
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
18 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Adults with end stage renal disease who are undergoing living donor kidney transplantation
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Potroić
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Risedronate
subjects received Risedronate for one year
|
risedronate 35 mg weekly
Inne nazwy:
|
|
Komparator placebo: subjects received placebo
subjects received placebo for 1 year
|
Risedronate Placebo 35 mg weekly
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Bone Mineral Density of Spine at 6 Months
Ramy czasowe: month 6 of the treatment
|
Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using the Hologic 4500 QDC scanner.
|
month 6 of the treatment
|
|
Bone Mineral Density of Spine at 12 Months
Ramy czasowe: month 12 of treatment
|
Bone Mineral Density (BMD) measurements were of the vertebral spine (L1-L4) measured using same Hologic 4500 QDC scanner.
|
month 12 of treatment
|
|
Bone Mineral Density of the Hip at 6 Months
Ramy czasowe: month 6 of the treatment
|
Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.
|
month 6 of the treatment
|
|
Bone Mineral Density of the Hip at 12 Months
Ramy czasowe: month 12 of the treatment
|
Bone mineral density (BMD) of the total hip were measured using the Hologic 4500 QDC scanner.
|
month 12 of the treatment
|
|
Bone Mineral Density of Forearm at 6 Months
Ramy czasowe: month 6 of the treatment
|
Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.
|
month 6 of the treatment
|
|
Bone Mineral Density of Forearm at 12 Months
Ramy czasowe: month 12 of the treatment
|
Bone mineral density (BMD) of the distal third of the nondialysis access forearm were measured using the Hologic 4500 QDC scanner.
|
month 12 of the treatment
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Bone Histomorphometry - Percent Bone Volume (BV/TV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Percent Bone Volume is the percentage of total volume occupied by calcified bone.
Percent Bone volume is calculated as Bone Volume (BV) divided by Tissue Volume (TV), where TV is bone plus marrow.
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Trabecular Thickness (TbTh)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
The ends of certain bones, known as cancellous bones, are actually not solid but are full of holes that are connected to each other by thin rods and plates of bone tissue known as trabeculae.
Trabeculae of bone provide structural support to the spongy bone found at the ends of long bones.
Trabeculae Trabecular Thickness (TbTh), a structural parameter, is the distance across individual trabecula.
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Mineralized Bone Volume (MdV/BV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Percent Mineralized Bone Volume is the percentage of Bone Volume consisting of mineralized bone.
Percent Mineralized Bone Volume is calculated as Mineralized Bone Volume (MdV) divided by Bone Volume (BV).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Mineralized Bone Volume (MdV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Bone mineralization is the process of laying down minerals on the matrix of the bone, with calcium and phosphorus as the most abundant minerals.
Mineralized Bone Volume (MdV) is the percentage of mineralized bone tissue.
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Osteoid Volume Relative to Bone Volume(OV/BV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue.
The reported values indicates the percent of a given volume of bone that consists of unmineralized bone.
It is equal to Osteoid Volume (OV) divided by Bone Volume (BV).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Osteoid Volume Relative to Tissue Volume (OV/TV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue.
The reported values indicates the percent of a given volume of tissue (bone + marrow) that consists of unmineralized bone.
It is equal to Osteoid Volume (OV) divided by Tissue Volume (TV).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Osteoid Surface Relative to Bone Surface (OS/BS)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue.
The reported values indicates the percent of bone surface that consists of unmineralized bone.
It is equal to Osteoid Surface (OS) divided by Bone Surface (BS).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Osteoblasts Relative to Bone Surface (OB/BS)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized.
Bone mass is a balance between the osteoblasts (OB) that form the bone and cells called osteoclasts (OC) that break down the bone.
The reported values indicate the percent of bone surface (BS) that is made up of osteoblasts (OB).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Osteoclasts Relative to Bone Surface (OC/BS)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones.
Osteoclasts make and secrete digestive enzymes that break up or dissolve the bone tissue.
Bone mass is a balance between the osteoblasts (OB) cells that form the bone and the osteoclasts (OC) cells that break down the bone.
The reported values indicate the percent of bone surface (BS) that consists of osteoclasts (OC).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Percent Eroded Surface Relative to Bone Surface (ES/BS)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoclasts (OC) are cells responsible for bone resorption, which is the breaking down of bones.
Osteoclasts make and secret digestive enzymes tha break up or dissolve the bone tissue.
An eroded surface (ES) is the surface of the lacuna ( a cavity or depression in the bone) generated by an active OC.
The reported values indicate the percent of eroded surface relative to bone surface (BS).
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Bone Formation Rate
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoblasts (OB) are cells that make bones by producing a matrix that becomes mineralized.
Bone formation rate (BFR) indicates how much of the bone is actively mineralizing; it is determined by the number of active OB and the average work of each OB.
|
Baseline and month 12 of the treatment
|
|
Bone Histomorphometry - Osteoid Volume (OV)
Ramy czasowe: Baseline and month 12 of the treatment
|
Bone histomorphometry is quantitative information on bone remodeling and structure, obtained through examination of an undecalcified bone biopsy.
Osteoid is the unmineralized, organic portion of the bone matrix that forms prior to the maturation of bone tissue.
The reported values indicates the Osteoid Volume (OV), the volume of bone that consists of unmineralized bone.
|
Baseline and month 12 of the treatment
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Śledczy
- Główny śledczy: Maria Coco, MD, MS, Montefiore Medical Center
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 października 2002
Zakończenie podstawowe (Rzeczywisty)
1 lipca 2008
Ukończenie studiów (Rzeczywisty)
1 lipca 2008
Daty rejestracji na studia
Pierwszy przesłany
15 grudnia 2005
Pierwszy przesłany, który spełnia kryteria kontroli jakości
15 grudnia 2005
Pierwszy wysłany (Oszacować)
19 grudnia 2005
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
1 marca 2019
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
5 lutego 2019
Ostatnia weryfikacja
1 lutego 2019
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 02-08-224
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Tak
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Renal Transplant Osteodystrophy
-
Fady M Kaldas, M.D., F.A.C.S.RekrutacyjnyOceny immunosupresji modulacji na Renal Recovery Post LTStany Zjednoczone
-
Abramson Cancer Center of the University of PennsylvaniaWycofanePacjenci z chorobą nowotworową poddawani przeszczepowi komórek macierzystych (RCT of ACP for Transplant)
Badania kliniczne na Risedronate
-
M.D. Anderson Cancer CenterProcter and GambleZakończony
-
Hanlim Pharm. Co., Ltd.Zakończony